tiprankstipranks
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H (SFOSF)
OTHER OTC:SFOSF
US Market

Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Income Statement

Compare
22 Followers

Shanghai Fosun Pharmaceutical (Group) Co Income Statement

Last quarter (Q3 2024), Shanghai Fosun Pharmaceutical (Group) Co's total revenue was ¥10.45B, an increase of 12.30% from the same quarter last year. In Q3, Shanghai Fosun Pharmaceutical (Group) Co's net income was ¥785.84M. See Shanghai Fosun Pharmaceutical (Group) Co’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
¥ 41.40B¥ 43.95B¥ 39.01B¥ 30.31B¥ 28.59B
Gross Profit
¥ 19.68B¥ 20.78B¥ 18.78B¥ 16.88B¥ 17.04B
Operating Expenses
¥ 16.50B¥ 17.15B¥ 16.06B¥ 14.05B¥ 14.43B
Depreciation and Amortization
¥ 2.97B¥ 2.34B¥ 1.83B¥ 1.67B¥ 1.47B
EBITDA
¥ 7.55B¥ 7.87B¥ 8.70B¥ 6.89B¥ 7.07B
Operating Income
¥ 3.31B¥ 8.30B¥ 6.31B¥ 4.72B¥ 6.41B
Other Income/Expenses
¥ -42.94M¥ -82.27M¥ -259.90M¥ -43.30M¥ -1.89B
Pretax Income
¥ 3.26B¥ 4.57B¥ 6.05B¥ 4.68B¥ 4.53B
Net Income
¥ 2.39B¥ 3.73B¥ 4.73B¥ 3.66B¥ 3.32B
Per Share Metrics
¥ ―¥ ―¥ ―¥ ―¥ ―
Basic EPS
¥ 0.89¥ 1.43¥ 1.85¥ 1.43¥ 1.30
Diluted EPS
¥ 0.89¥ 1.43¥ 1.85¥ 1.43¥ 1.30
Weighted Average Shares Outstanding
2.68B 2.61B 2.56B 2.56B 2.56B
Weighted Average Shares Outstanding (Diluted)
2.67B 2.61B 2.56B 2.56B 2.56B
Currency in CNY

Shanghai Fosun Pharmaceutical (Group) Co Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis